Exploring Asthma Exacerbation in Mepolizumab Treated Patients
Research type
Research Study
Full title
Exacerbation Profile in Patients on Mepolizumab for Severe Refractory Eosinophilic Asthma - an Exploratory Study
IRAS ID
232036
Contact name
Liam Heaney
Contact email
Duration of Study in the UK
2 years, 8 months, 1 days
Research summary
In this study, we hope to characterise events of worsening asthma in patients taking mepolizumab to try and establish if they have evidence of inflammation which may respond to oral corticosteroids when their asthma symptoms worsen: this will be done by looking at markers of asthma in their blood, urine, sputum and exhaled breath.
REC name
HSC REC B
REC reference
17/NI/0173
Date of REC Opinion
12 Sep 2017
REC opinion
Favourable Opinion